Literature DB >> 24141556

Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.

Hidekazu Suzuki1, Kazuhiro Asami, Tomonori Hirashima, Norio Okamoto, Tadahiro Yamadori, Motohiro Tamiya, Naoko Morishita, Takayuki Shiroyama, Sawa Takeoka, Akio Osa, Yuichiro Azuma, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Ichiro Kawase.   

Abstract

PURPOSE: Prognostic factors and complicated prognostic models have been proposed for malignant pleural mesothelioma (MPM). This study was designed to stratify MPM prognosis by using a simple model.
METHODS: Patients diagnosed with MPM in the past 10 years (n = 122) were examined retrospectively. Data on the presence of chest pain, performance status (PS), asbestos exposure, smoking status, white blood cell count (WBC), haemoglobin (Hb) concentration, platelet count (PLT), lactate dehydronate (LD), histology, stage, and date of death or censored status were collected. After the factors were examined in the univariate analysis, recursive partitioning analysis was performed.
RESULTS: Statistically significant factors related to survival were the type of histology, stage, PS, WBC, PLT, Hb concentration, and LD. Histology, stage, PS, and Hb concentration were used in multivariate analysis. Stage and Hb concentration showed good statistical significance, whereas PS was borderline significant. The survival analyses were stratified into five groups by PS, stage, Hb concentration, and chest pain using recursive partitioning analysis. Group A comprised patients showing the most favourable prognoses (PS 0-2 and Hb concentration >12.1 g dL(-1) or PS 0-2 and Hb concentration ≤12.1 g dL(-1) without pain), and group B comprised the remaining patients. The median overall survival in groups A and B was 563 days (95 % confidence interval [CI] 502-779) and 157 days (95 % CI 115-224), respectively (hazard ratio of 5.44 [3.46-8.53, P < 0.0001]).
CONCLUSIONS: The MPM patients with PS 0-2 and Hb concentration >12.1 or ≤12.1 g dL(-1) without chest pain had favourable prognoses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24141556     DOI: 10.1007/s00408-013-9516-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  19 in total

1.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  Prognostic factors in malignant pleural mesothelioma: a retrospective study.

Authors:  Hidekazu Suzuki; Tomonori Hirashima; Masashi Kobayashi; Norio Okamoto; Yuka Matsuura; Motohiro Tamiya; Naoko Morishita; Kohei Okafuji; Takayuki Shiroyama; Osamu Morimura; Satomu Morita; Ichiro Kawase
Journal:  Intern Med       Date:  2012-04-01       Impact factor: 1.271

3.  Incidence and survival of mesothelioma in Osaka, Japan.

Authors:  Naoko Kanazawa; Akiko Ioka; Hideaki Tsukuma; Wakiko Ajiki; Akira Oshima
Journal:  Jpn J Clin Oncol       Date:  2006-04       Impact factor: 3.019

4.  Robust data: the essential foundation of a revised staging system for pleural mesothelioma.

Authors:  Hedy Lee Kindler
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

Review 5.  Malignant pleural mesothelioma: factors influencing the prognosis.

Authors:  Tommaso Claudio Mineo; Vincenzo Ambrogi
Journal:  Oncology (Williston Park)       Date:  2012-12       Impact factor: 2.990

6.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

7.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

Authors:  J E Herndon; M R Green; A P Chahinian; J M Corson; Y Suzuki; N J Vogelzang
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

8.  Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.

Authors:  Steven C Kao; Janette Vardy; Mark Chatfield; Peter Corte; Nick Pavlakis; Christopher Clarke; Nico van Zandwijk; Stephen Clarke
Journal:  Clin Lung Cancer       Date:  2012-06-01       Impact factor: 4.785

9.  Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.

Authors:  Shuko Nojiri; Kenichi Gemba; Keisuke Aoe; Katsuya Kato; Takuhiro Yamaguchi; Tsugumichi Sato; Kiyoshi Kubota; Takumi Kishimoto
Journal:  Jpn J Clin Oncol       Date:  2010-08-26       Impact factor: 3.019

10.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

View more
  5 in total

1.  Recursive partitioning analysis of lymph node ratio in breast cancer patients.

Authors:  Yao-Jen Chang; Kuo-Piao Chung; Li-Ju Chen; Yun-Jau Chang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

2.  Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis.

Authors:  Yi Zhuo; Lanying Lin; Shushan Wei; Mingwei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

3.  Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Authors:  Mohamed Rahouma; Hala Aziz; Galal Ghaly; Mohamed Kamel; Iman Loai; Abdelrahman Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

4.  Does size matter? -a population-based analysis of malignant pleural mesothelioma.

Authors:  Jiaxi He; Songhui Xu; Hui Pan; Shuben Li; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2020-08

5.  Recursive Partitioning Analysis of Fractional Low-Frequency Fluctuations in Narcolepsy With Cataplexy.

Authors:  Xiao Fulong; Lu Chao; Zhao Dianjiang; Zou Qihong; Zhang Wei; Zhang Jun; Han Fang
Journal:  Front Neurol       Date:  2018-11-02       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.